



## **GlycoMimetics to Present at Upcoming Investor Conferences**

April 4, 2019

ROCKVILLE, Md.--(BUSINESS WIRE)--Apr. 4, 2019-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that senior management will present corporate updates at two upcoming investor conferences in April. Details are as follows:

### **HC WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE**

*Who:* Chief Financial Officer Brian Hahn  
*When:* Tuesday, April 9 at 2:10 p.m. (GMT)  
*Where:* London, UK

### **18<sup>TH</sup> ANNUAL NEEDHAM HEALTHCARE CONFERENCE**

*Who:* Chief Executive Officer Rachel King  
*When:* Wednesday, April 10 at 3:30 p.m. (ET)  
*Where:* New York, NY

To access the live webcast and subsequent archived recordings for each of these presentations, please visit the GlycoMimetics website at [www.glycomimetics.com](http://www.glycomimetics.com).

### **About GlycoMimetics, Inc.**

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190404005543/en/>

Source: GlycoMimetics, Inc.

### **Investor Contact:**

Shari Annes  
Phone: 650-888-0902  
Email: [sannes@annesassociates.com](mailto:sannes@annesassociates.com)

### **Media Contact:**

Jamie Lacey-Moreira  
Phone: 410-299-3310  
Email: [jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)